期刊文献+

TRAIL基因原核表达载体的构建、表达与抗体制备

Construction of Prokarytoic Expression Vector of TRAIL Gene and Preparation of Anti-TRAIL Antibody
下载PDF
导出
摘要 目的:获取抗肿瘤坏死因子相关凋亡诱导配体(TRAIL)抗体。方法:利用PCR技术和基因重组技术将TRAIL基因构建于原核表达载体pPreTMH-Tb中,经酶切、测序鉴定证实构建完全正确后,通过IPTG诱导在大肠杆菌DH-5α中获得表达,并将TRAIL蛋白免疫家兔,通过Dot blot及Western blot检测抗TRAIL抗体的产生。结果:成功构建TRAIL基因原核表达载体,并在大肠杆菌DH-5α中获得表达,TRAIL蛋白表达量占菌体蛋白质总量的11.8%,Dot blot及Western blot检测证实获得了抗TRAIL抗体。结论:成功制备抗TRAIL抗体,这为TRAIL在真核细胞水平研究奠定了实验基础。 Objective: To obtain the anti-TRAIL antibody. Methods: A prokaryotic expression vector pPre-TMHTb was constructed by PCR and recombinant DNA techniques and was confirmed by enzymatic digestion and sequence analysis. TRAIL protein induced to express by IPTG in E. coli DH-5α. After TRAIL protein immunised rabbits, anti-TRAIL antibody was tested by Dot blot and Western blot. Results:A prokaryotic expression vector pPre-TMHTb was constructed and expressd in E. coli DH-5α. TRAIL protein was detected up to 11.8% of the total bacterial protein expressed and anti-TRAIL antibody was tested by Dot blot and Western blot. Conclusions: The anti-TRAIL antibody was obtained that provides an experimental basis for the studies of TRAIL in eukaryotic level.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2004年第1期50-53,共4页 Chinese Journal of Cancer Biotherapy
基金 贵州省省长专项(No.S2001-14)资助
关键词 肿瘤坏死因子相关凋亡诱导配体 基因表达 大肠杆菌 TNF-related apoptosis-inducing ligand gene expression escherichia coli
  • 相关文献

参考文献13

  • 1薛胜利,冯作化,张桂梅,张慧,黎培员,李东.TRAIL真核表达治疗肝细胞癌作用的研究[J].中国肿瘤生物治疗杂志,2002,9(3):158-162. 被引量:5
  • 2Wiley SR, Schooley K. Identification andcharactefization of a new member of the TNF family that induces apoptosis [ J ]. Immunity,1995, 3 : 673-682.
  • 3Bonavida B, Ng CP, Jazirehi A, et al. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The TRAIL TO nontoxic cancer therapeutics [ J ]. Int J Oncol, 1999, 15 :793 -802.
  • 4EI-Deiry WS. The TRAIL to an anti-cancer agent [ J]. Drug Resist, 1999, 2: 79-80.
  • 5Keane MM, Ettenberg SA, Nau MM, et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell line [ J ]. Cancer Res, 1999, 59: 734-741.
  • 6Griffith TS, Broghammer EL, et al. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus[ J]. Mol Ther, 2001, 4: 257-266.
  • 7Yamashita Y, Shimada M,Tanaka S, et al. Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand(TRA1L)/Apo2L gene therapy for hepatocellular carcinoma[ J].Hum Gene Ther, 2002, 13: 275-286.
  • 8Yamashita Y, Shimada M,Tanaka S, et al. Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocellular carcinoma [J].Hum Gene Ther, 2002, 13: 275-286.
  • 9Wiley SR, Schooley K. Identification andcharacterization of a new member of the TNF family that induces apoptosis[J]. Immunity,1995, 3: 673-682.
  • 10Bonavida B, Ng CP, Jazirehi A, et al. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The TRAIL TO nontoxic cancer therapeutics [J]. Int J Onco1, 1999, 15:793 -802.

二级参考文献4

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部